N/A N=100 Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System.
Ventricular Fibrillation · Ventricular Tachycardia
Primary: Number of Patients With Skin Symptoms — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=124 Effects of an Anal Insert Device in Fecal Incontinence
Fecal Incontinence
Primary: Primary Effectiveness Endpoint — 75.9 percentage of treatment responders
Phase 3 N=62 Methotrexate - Inadequate Response Device Sub-Study
Rheumatoid Arthritis (RA)
Primary: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs…
Phase 2 N=47 Efficacy Study of a Facemask Device to Treat Hypotension
Hypotension
Primary: Rise in Systolic Blood Pressure Over the First 10 Minutes of Use Compared to Baseline — 5.9; 12.9 mm Hg
Phase 3 N=20 Saizen® E-Device User Trial
Growth Disorders
Primary: Subjects' Overall Impression After Using E-Device — 0; 7; 13 subjects
N/A N=48 Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device
Wrinkle · Benign Pigmented Lesions · Benign Vascular Lesions
Primary: Number of Subjects Who Noticed Improvement — 10; 34 Participants
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
N/A N=136 Ingenio Device Algorithm Study
Sinus Node Disease · AV Block · Heart Failure
Primary: Accuracy of Commanded Right Atrial Automatic Threshold (RAAT) — 100 percentage of accurate RAAT tests
N/A N=162 Detect Fluid Early From Intra-thoracic Impedance Monitoring
Heart Failure
Primary: False Positive Rate — 1.8; 1.49 departures from device threshold
N/A N=145 Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
Coronary Artery Disease · Myocardial Infarction
Primary: Percentage of Participants Who Experienced Freedom From Major Adverse Cardiac Events (MACE) Within 30 Days Post-procedure — 98.6 Percentage of participants
N/A N=14 Electrical Stimulation in Diabetic Peripheral Neuropathy
NMES · Control
Primary: Nerve Conduction Speed (Common Peroneal Nerve) — 33.93; 44.1; 41.63; 44.13 m/sec
N/A N=99 Safety and Effectiveness of an Auricular Spray
Excessive Ear Wax
Primary: Skin Irritation — 0.22; 0.20; 0.13; 0.11 score on a scale
Phase 1 N=20 Performance and Safety Evaluation of an Intradermal Delivery Device
Injections, Intradermal
Primary: Proportion of Injections Delivered to the Intradermal Layer of the Skin — 1 percentage of injections
N/A N=9 Clinical Study to Assess the Effectiveness of the Device Patello
Passiv Continuous Patella Mobilisation
Primary: Patellofemoral Translation — 0.819; 0.734; 0.776; 0.771 cm
N/A N=90 A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI)
Stress Urinary Incontinence (SUI)
Primary: Percentage of Responders for Pad Weight Gain or SUI Episodes — 69 percentage of subjects
N/A N=71 ivWatch Model 400: Device Validation for Infiltrated Tissues
Infiltration of Peripheral IV Therapy
Primary: Red Notification Sensitivity to Infiltrated Tissues — 96.4 percentage of infiltrations
N/A N=15 Evaluation of Extended Wear Technology
Hearing Loss
Primary: Subjective Questionnaire of Comfort — 0; 0 score on a scale
Phase 1 N=3 Two Devices for Reflex Voiding Following Spinal Cord Injury
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants
N/A N=25 Silk'n HST Device Usability and Self Selection Study
Wrinkles
Primary: Usability Assessment — 25 Participants
N/A N=12 The Passy Muir Swallowing Self Training Device
Oropharyngeal Dysphagia
Primary: Change in Swallow Frequency 30 Hz — 0.512 Change in swallows/min — p=0.218
N/A N=86 Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices Viscol
Aesthetic Dermatology
Primary: Performance at 1 Month Investigator Overall VISCOL Range — 77 Participants — p=<0.0001
N/A N=53 Effects of Device-assisted Practice of ADL on Arm/Hand Recovery in Individuals With Moderate to Severe Stroke
Stroke
Primary: Box and Blocks Test (BBT) — 5.7; 8.8 blocks
N/A N=30 Electronic Device Implantation Through Remote Guidance
Telemedicine · Heart Failure · Defibrillators
Primary: Percentage of Participants With Interventional Procedures Successfully Completed — 10; 20 Participants
N/A N=1,999 InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry
Heart Failure · Cardiomyopathy
Primary: Overall Death Rate and Cause Specific Death Rate During Three Years Post Implant. — 450; 213 participants
N/A N=99 ivWatch Sensor: Device Validation for Infiltrated Tissues
Infiltration of Peripheral IV Therapy
Primary: Red Notification Sensitivity to Infiltrated Tissues — 99.0; 99.0 percentage of infiltrations detected
N/A N=76 DESIVI: Dosing of Electrical Stimulation in Venous Insufficiency
Varicose Veins · Venous Stasis · Venous Insufficiency
Primary: Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV — 3.36; 26.58; 39.49; 0.46 percentage change from device off
N/A N=43 ivWatch Model 400: Device Validation for Non-Infiltrated Tissues
Infiltration of Peripheral IV Therapy
Primary: Normal Tissue Red Notification Rate — 0.24 red notifications per day
N/A N=88 Non-invasive CTS Device Clinical Trial
Carpal Tunnel Syndrome
Primary: BCTQ SSS at 8 Weeks vs Baseline — 2.16; 2.32; -0.62; -0.64 score on a scale
Phase 3 N=206 Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups…
Phase 2 N=35 Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices
Asthma
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose for Each Treatment — 2.97; 2.93; 2.91; 2.77 Liters